Clinical Trials Sponsored by Neurotec Pharma

Total 8446 results

HRA Pharma

Completed

Safety and Efficacy of CDB-2914 for Emergency Contraception

Emergency Contraception

United States
LEO Pharma

Terminated

Recombinant Human Antithrombin (ATryn®) in the Treatment of Patients With DIC Associated With Severe Sepsis

Disseminated Intravascular Coagulation
Kukje Pharma

Completed

[KSR-001-P01]Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristic of KSR-001

Dry Eye Syndromes

Korea, Republic of
LEO Pharma

Completed

Clinical Trial to Evaluate UV-light-induced Allergic Skin Reactions After Application of Delgocitinib Cream

Healthy Volunteers

Germany
Zealand Pharma

Completed

A Bridging Trial to Compare the PK Profile When Glepaglutide is Administered Via Vial/Syringe Versus Autoinjector.

Healthy

Netherlands
Zealand Pharma

Completed

A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects

Hypoglycemia | Diabetes Mellitus, Type 1

Canada, United States, Austria, Germany
LEO Pharma

Completed

Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Keratosis

Actinic Keratosis

United States
Kiadis Pharma

Completed

Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome

Canada, Belgium, Germany, Croatia, United Kingdom, Portugal
LEO Pharma

Completed

Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema

Chronic Hand Eczema

United States, Germany, Denmark
LEO Pharma

Completed

Body PSOriasis: Long-term Relapse CONTROL (PSO-CONTROL)

Psoriasis Vulgaris

Russian Federation
LEO Pharma

Completed

Safety and Tolerability of LEO 138559 in Healthy Subjects and Subjects With Atopic Dermatitis

Atopic Dermatitis

United Kingdom
UCB Pharma

Completed

Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE) (EMBODY2)

Systemic Lupus Erythematosus

United States, Brazil, Canada, France, Germany, Hungary, India, Italy, Mexico, Poland, Romania, Russian Federation, South Africa, Spain, Ukraine, United Kingdom
Zealand Pharma

Completed

A Single Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570

Healthy

Germany
UCB Pharma

Completed

A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis

Rheumatoid Arthritis

United States, Canada, Belgium, Argentina, Israel, Bulgaria, Chile, Russian Federation, Australia, Czechia, Latvia, Ukraine, Croatia
UCB Pharma

Completed

A Study of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis

Rheumatoid Arthritis

United States, Poland, Israel, Bulgaria, Serbia, Ukraine, Chile, Russian Federation, Lithuania, Mexico, Czechia, Latvia, Croatia, Estonia, Slovakia
LEO Pharma

Completed

Clinical Trial to Evaluate Light-induced Skin Reactions After Application of Delgocitinib Cream

Healthy Volunteers

Germany
LEO Pharma

Completed

Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamics Effect of Calcipotriol/Betamethasone Dipropionate in a New Administration Form in Subjects With Chronic Plaque Psoriasis.

Psoriasis Vulgaris

Germany
LEO Pharma

Completed

LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris

Psoriasis Vulgaris

United States, Canada, Germany, United Kingdom, France, Poland
UCB Pharma

Completed

Efficacy and Tolerability of Levetiracetam Add-On Treatment in Refractory Pediatric Patients With Partial Onset Seizures

Epilepsy
UCB Pharma

Completed

A Study to Look at the Efficacy and Safety of Keppra® Extended Release Formulation - XR

Epilepsy

Brazil, Finland, India, Mexico, Russian Federation, South Africa, Ukraine
Orphelia Pharma

Completed

Bioequivalence Study of Vigabatrin ORPHELIA Pharma 500mg Soluble Tablets and SabrilTM 500mg Granules for Oral Administration

Therapeutic Equivalency

France
pH Pharma

Completed

A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Doses of PHP-303 in Otherwise Healthy Overweight or Obese Subjects

Otherwise Healthy Overweight or Obese

United States
UCB Pharma

Completed

A Study of the Safety and Effectiveness of Liquid Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis

Rheumatoid Arthritis

United States, Bulgaria, Croatia, Czechia, Estonia, Israel, Latvia, Lithuania, Poland, Russian Federation, Serbia, Slovakia, Ukraine
LEO Pharma

Completed

Non Interventional Study of the Validation of the Ottawa Score in Cancer Patients With Venous Thromboembolism (VTE) (PREDICARE)

Venous Thromboembolism

France
LEO Pharma

Completed

LEO 29102 Cream in the Treatment of Atopic Dermatitis

Atopic Dermatitis

Canada, Finland, Germany
HRA Pharma

Terminated

Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion

Cushing's Syndrome

United States, Netherlands, France, Italy, Germany
LEO Pharma

Completed

LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris

Psoriasis Vulgaris

United States
Enyo Pharma

Completed

Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C]-EYP001a After a Single Oral Dose

Healthy

Netherlands
Getz Pharma

Completed

Zurig (Febuxostat) 40mg Efficacy and Safety Trial (ZEST)

Hyperuricemia

Pakistan
LEO Pharma

Completed

A Trial to Investigate the Safety, Tolerability, and Drug Levels in Blood After Single and Multiple Doses of LEO 32731 in Healthy People

Healthy

United Kingdom
Pila Pharma

Completed

A Single-dose Trial to Investigate the Safety and Tolerability of XEN-D0501 in Patients With Diabetes Mellitus Type 2

Diabetes Mellitus, Type 2

Denmark
Noden Pharma

Completed

52-104 Week Off-therapy Second Extension to Study CSPP100A2365

Hypertension

Turkey, United States, Guatemala, Slovakia, Hungary, Puerto Rico, Poland
UCB Pharma

Completed

A Study Assessing Efficacy of Brivaracetam in Subjects With Persistent Pain After Shingles (Post-herpetic Neuralgia)

Neuralgia, Postherpetic

Poland, United Kingdom, Belgium, Spain, Bulgaria, Germany, Serbia, France, Slovakia, Czechia
LEO Pharma

Completed

Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis

Actinic Keratosis

United States, Canada
LEO Pharma

Completed

Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up

Actinic Keratosis

United States
ERYtech Pharma

No longer available

Expanded Access Program: Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA®) in Combination With Polychemotherapy in Patients Under 55 Years Old With Acute Lymphoblastic Leukemia (ALL) at Risk to Receive Other Formulation of Asparaginase (EAP)

Acute Lymphoblastic Leukemia

France
LEO Pharma

Completed

Pharmacokinetics of Ingenol Mebutate Gel in Actinic Keratosis Under Maximum Use Conditions

Actinic Keratosis

United States
pH Pharma

Completed

Evaluation of PHP-201 Ophthalmic Solution in Patients With Normal Tension Glaucoma

Normal Tension Glaucoma

Korea, Republic of
Getz Pharma

Completed

Effect of Ivabradine in Lowering Heart Rate and Quality of Life in Chronic Heart Failure Patients

Chronic Heart Failure
Horus Pharma

Unknown

Evaluation of Efficacy and Safety of Vismed Gel Multi 0.3% Versus Vismed Multi 0.18% on Treatment of Ocular Dryness

Dry Eye
UCB Pharma

Completed

Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease (COSPAR II)

Crohn's Disease

United States, Germany, Canada
UCB Pharma

Completed

Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines

Rheumatoid Arthritis

United States
ERYtech Pharma

Completed

Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma

Pancreatic Adenocarcinoma Metastatic

France
LEO Pharma

Completed

The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo

Impetigo | Secondarily Infected Traumatic Lesions (SITL)

United States
UCB Pharma

Completed

eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam (VERVE)

Epilepsy

United States, Australia, Bulgaria, Denmark, France, Germany, Romania, Spain, Sweden
UCB Pharma

Terminated

A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures

Epilepsy

United States, France, Germany, Spain, Hungary, Italy
UCB Pharma

Completed

An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam

Epilepsy

Canada, United States, Australia, Belgium, Czechia, France, Germany, Hungary, Italy, Spain, Sweden
UCB Pharma

Completed

Open-label, Pharmacokinetic, Safety and Efficacy Study of Adjunctive Brivaracetam in Children With Epilepsy.

Epilepsy

Spain, United States, Belgium, Czechia, Mexico, Poland
ERYtech Pharma

Terminated

L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) for Treatment of Adult Patients With ALL or LBL

Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma

United States
Kukje Pharma

Unknown

[KJ-INT-002] BE Study

Gastritis

Korea, Republic of

3

Subscribe